APA (7th ed.) Citation

S, D., F, Z., DA, D., EP, M., JJ, W., RJ, G., . . . KT, F. (2022). Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40(14), 1552. https://doi.org/10.1200/JCO.21.01648

Chicago Style (17th ed.) Citation

S, Damodaran, et al. "Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 40, no. 14 (2022): 1552. https://doi.org/10.1200/JCO.21.01648.

MLA (9th ed.) Citation

S, Damodaran, et al. "Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 40, no. 14, 2022, p. 1552, https://doi.org/10.1200/JCO.21.01648.